Are health technology assessments of pharmacogenetic tests feasible? A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen

dc.contributor.author	Fleeman, N.	spa
dc.contributor.author	Payne, K.	spa
dc.contributor.author	Newman, W. G.	spa
dc.contributor.author	Howell, S. J.	spa
dc.contributor.author	Boland, A.	spa
dc.contributor.author	Oyee, J.	spa
dc.contributor.author	Martín Saborido, Carlos	spa
dc.contributor.author	Fernández Santander, Ana	spa
dc.contributor.author	Dickson, R.	spa
dc.date.accessioned	2014-03-18T10:09:13Z
dc.date.available	2014-03-18T10:09:13Z
dc.date.issued	2013	spa
dc.identifier.citation	Fleeman, N., Payne, K., Newman, W. G., Howell, S. J., Boland, A., Oyee, J., ..., & Dickson, R. (2013). Are health technology assessments of pharmacogenetic tests feasible? A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen. Personalized Medicine, 10(6), 601-611.	spa
dc.identifier.uri	http://hdl.handle.net/11268/2129
dc.language.iso	eng	spa
dc.title	Are health technology assessments of pharmacogenetic tests feasible? A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen	spa
dc.type	article	spa
dc.description.impact	1.132 JCR (2013) Q4, 196/254 Pharmacology & pharmacy	spa
dc.identifier.doi	10.2217/pme.13.60	spa
dc.rights.accessRights	closedAccess	en
dc.subject.unesco	Cáncer	spa
dc.subject.unesco	Tratamiento médico	spa
dc.peerreviewed	Si	spa